ESALY News and Press, Eisai Co. Ltd. ADR From 08/24/22

Summary Q2 results are on the table and Idorsia could convince with encouraging developments in its pipeline and its initial commercial efforts with QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan). The Swiss and Canadian health authorities are supposed to give their feedback on QU...

Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays TOKYO, Aug 24, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics ("C...

Eisai ( OTCPK:ESALY ) ( OTCPK:ESALF ) and C2N Diagnostics entered a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis es...

Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care TOKYO, Aug 9, 2022 - (JCN Newswire) - Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capit...

Eisai Co., Ltd. (ESALY) Q1 2023 Earnings Conference Call August 5, 2022 3:00 AM ET Company Participants Tatsuyuki Yasuno - SVP, CFO & Chief IR Officer Ivan Cheung - SVP, Global Alzheimer's Disease Officer, President, Americas Region Chairman & CEO, Eisai Inc....

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2023 Q1 earnings call. For further details see: Eisai Co., Ltd. 2023 Q1 - Results - Earnings Call Presentation

Eisai ( OTCPK:ESALY ): Q1 GAAP EPS of ¥167.25. Revenue of ¥756.22M (+17.1% Y/Y) misses by ¥433.78M . For further details see: Eisai GAAP EPS of ¥167.25, revenue of ¥756.22M misses by ¥433.78M

Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022 TOKYO and CAMBRIDGE, Mass., Aug 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced that Eisai presen...

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial TOKYO and RAHWAY, N.J., Aug 4, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase ...

Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership PR Newswire Thomas D. Fagan Jr. Appointed Vice President, U.S. Alzheimer's Disease Commercial at Eisai Inc. NUTLEY, N.J. , July 27, 2022 /PRNewswire/ -- Eisai Inc., t...